What's new

Opinion/decision on a Paediatric investigation plan (PIP): Quviviq, Daridorexant, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders, PIP number: P/0054/2024

Opinion/decision on a Paediatric investigation plan (PIP): Quviviq, Daridorexant, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders, PIP number: P/0054/2024

Apr 2, 2025 - 10:25
 0
Opinion/decision on a Paediatric investigation plan (PIP): Quviviq, Daridorexant, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders, PIP number: P/0054/2024
Opinion/decision on a Paediatric investigation plan (PIP): Quviviq, Daridorexant, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders, PIP number: P/0054/2024
Read More

Tags:

Previous Article

Danish confectionery brand, LAKRIDS BY BÜLOW, experiences one of its best years ...

Next Article

MDA Space moves to acquire SatixFy in digital satellite expansion

Related Posts

Joint EC/HMA/EMA multi-stakeholder workshop on pharmacogenomics, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 24 September 2024, 09:00 (CEST) to 24 September 2024, 17:00 (CEST)

Joint EC/HMA/EMA multi-stakeholder workshop on pharmaco...

Feb 26, 2025  0

Clinical Trials Information System (CTIS): Information day, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 22 May 2025, 12:30 (CEST) to 22 May 2025, 17:30 (CEST)

Clinical Trials Information System (CTIS): Information ...

Mar 28, 2025  0

Call for scientific data for the periodic review of the...

Apr 1, 2025  0